Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
NVS:BCBA
Novartis CEDEAR
10 800,00 ARS
0,00%
(0,00) 1D
19-апр., 16:40:36 GMT-3  ·   ARS
All symbols
SymbolPriceChange% Change
Generating top insights for NVS...
Mkt. cap
295,57 млд
Volume
0,00
Shares outstanding
2,03 млд
No. of employees
75 миң
News stories
From sources across the web
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis CEDEAR
CEOVasant Narasimhan
Employees75,3 миң
Founded1996-ж., 29-фев.
HeadquartersБазель, Базель-Штадт, Швейцария
SectorPharmaceutical industry
Websitenovartis.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
14,84 млд
14,36 млд
13,86 млд
13,52 млд
Cost of goods sold
3,32 млд
3,54 млд
3,54 млд
3,44 млд
Cost of revenue
3,32 млд
3,54 млд
3,54 млд
3,44 млд
Research and development expenses
2,62 млд
2,86 млд
2,84 млд
2,78 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,44 млд
3,30 млд
3,44 млд
3,14 млд
Operating expense
6,05 млд
6,24 млд
6,46 млд
5,96 млд
Total operating expenses
9,37 млд
9,77 млд
10,00 млд
9,40 млд
Operating income
5,46 млд
4,58 млд
3,86 млд
4,12 млд
Other non operating income
-13,00 млн
-7,00 млн
-130,00 млн
4,00 млн
EBT including unusual items
4,53 млд
4,20 млд
3,22 млд
3,84 млд
EBT excluding unusual items
5,16 млд
4,29 млд
3,49 млд
3,78 млд
Income tax expense
507,00 млн
266,00 млн
814,00 млн
683,00 млн
Effective tax rate
11,19%
6,34%
25,30%
17,79%
Other operating expenses
-4,00 млн
70,00 млн
190,00 млн
42,00 млн
Net income
4,04 млд
3,93 млд
2,41 млд
3,16 млд
Net profit margin
27,24%
27,36%
17,38%
23,34%
Earnings per share
2,42
2,25
2,03
1,99
Interest and investment income
-
-
373,00 млн
-
Interest expense
-289,00 млн
-281,00 млн
-304,00 млн
-343,00 млн
Net interest expenses
-289,00 млн
-281,00 млн
69,00 млн
-343,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
6,56 млд
5,78 млд
4,96 млд
5,24 млд
Gain or loss from assets sale
-67,00 млн
81,00 млн
80,00 млн
-159,00 млн
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer